About Repligen Corporation
https://www.repligen.comRepligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
CEO
Olivier Loeillot
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 226
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Evercore ISI Group
Outperform
RBC Capital
Outperform
Barclays
Overweight
Wells Fargo
Overweight
JP Morgan
Overweight
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:7.57M
Value:$1.23B
BLACKROCK, INC.
Shares:6.14M
Value:$994.82M
VANGUARD GROUP INC
Shares:5.04M
Value:$817.31M
Summary
Showing Top 3 of 584
About Repligen Corporation
https://www.repligen.comRepligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $188.81M ▲ | $83.69M ▲ | $14.91M ▲ | 7.9% ▼ | $0.27 ▲ | $46.94M ▼ |
| Q2-2025 | $182.37M ▲ | $77.25M ▼ | $14.87M ▲ | 8.15% ▲ | $0.26 ▲ | $48.34M ▲ |
| Q1-2025 | $169.17M ▲ | $84.18M ▲ | $5.83M ▲ | 3.45% ▲ | $0.1 ▲ | $36.38M ▲ |
| Q4-2024 | $167.55M ▲ | $75.34M ▼ | $-33.87M ▼ | -20.21% ▼ | $-0.6 ▼ | $2.11M ▼ |
| Q3-2024 | $154.87M | $85.32M | $-654K | -0.42% | $0.32 | $21.39M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $748.75M ▲ | $2.92B ▲ | $840.62M ▲ | $2.08B ▲ |
| Q2-2025 | $708.86M ▲ | $2.9B ▲ | $839.89M ▼ | $2.06B ▲ |
| Q1-2025 | $697.23M ▼ | $2.85B ▲ | $866.66M ▲ | $1.99B ▲ |
| Q4-2024 | $757.36M ▼ | $2.83B ▼ | $856.95M ▲ | $1.97B ▼ |
| Q3-2024 | $783.96M | $2.83B | $813.96M | $2.02B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $14.91M ▲ | $48.1M ▲ | $-7.78M ▲ | $-239K ▲ | $39.89M ▲ | $42.71M ▲ |
| Q2-2025 | $14.87M ▲ | $28.61M ▲ | $-7.84M ▲ | $-10.13M ▼ | $11.63M ▲ | $21M ▲ |
| Q1-2025 | $5.83M ▲ | $15.01M ▼ | $-74.11M ▼ | $-5.03M ▼ | $-60.13M ▼ | $10.57M ▼ |
| Q4-2024 | $-33.87M ▼ | $39.18M ▼ | $-64.76M ▼ | $1.45M ▲ | $-26.61M ▼ | $32.19M ▼ |
| Q3-2024 | $-654K | $49.32M | $-5.86M | $-69.6M | $-25.18M | $42.18M |
Revenue by Products
| Product | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 Product | $170.00M ▲ | $180.00M ▲ | $170.00M ▼ | $190.00M ▲ |
 Royalty | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Olivier Loeillot
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 226
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Evercore ISI Group
Outperform
RBC Capital
Outperform
Barclays
Overweight
Wells Fargo
Overweight
JP Morgan
Overweight
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:7.57M
Value:$1.23B
BLACKROCK, INC.
Shares:6.14M
Value:$994.82M
VANGUARD GROUP INC
Shares:5.04M
Value:$817.31M
Summary
Showing Top 3 of 584